Functional vs Absolute Iron Deficiency Anemia: Key Distinctions
Absolute iron deficiency reflects depleted iron stores with TSAT ≤20% and ferritin <100 ng/mL (non-dialysis/peritoneal dialysis) or <200 ng/mL (hemodialysis), while functional iron deficiency occurs when iron stores are adequate (ferritin >100 ng/mL) but iron cannot be mobilized quickly enough to meet erythropoietic demands, typically due to inflammation-mediated hepcidin elevation or ESA-stimulated erythropoiesis. 1, 2
Pathophysiology
Absolute Iron Deficiency
- Depleted total body iron stores with impaired iron delivery to erythroid marrow 2
- Results from inadequate dietary intake, malabsorption (celiac disease, bariatric surgery, autoimmune gastritis), or chronic blood loss 3
- Both serum ferritin and transferrin saturation are low, reflecting true iron depletion 4
Functional Iron Deficiency
- Adequate or elevated iron stores that cannot be mobilized to support erythropoiesis 2
- Two distinct mechanisms exist: 1
- Inflammation-mediated iron sequestration: Chronic inflammation increases hepcidin production, which blocks iron absorption in the gut and traps iron in macrophages of the reticuloendothelial system 2, 5
- Kinetic iron deficiency: ESA-stimulated bursts of erythropoiesis create demand that exceeds the rate of iron mobilization from stores 1, 2
- Common in chronic kidney disease (especially dialysis patients on ESA therapy), chronic heart failure (40-70% prevalence), and inflammatory bowel disease 2
Laboratory Findings
Absolute Iron Deficiency
- TSAT ≤20% 1, 4
- Ferritin <100 ng/mL (non-dialysis/peritoneal dialysis CKD) or <200 ng/mL (hemodialysis) 1, 4
- In healthy individuals without inflammation, ferritin <12 ng/mL indicates depleted stores 2
- Reticulocyte hemoglobin content decreased 1
Functional Iron Deficiency
- TSAT ≤20% (indicating insufficient iron availability for erythropoiesis) 1, 4
- Ferritin >100 ng/mL (non-dialysis) or >200 ng/mL (hemodialysis), often 100-700 ng/mL 2, 4
- Elevated erythrocyte protoporphyrin concentration due to limited iron availability for hemoglobin synthesis 2
- Increased percentage of hypochromic RBCs and reduced reticulocyte hemoglobin content 1
Critical Diagnostic Caveats
- Current diagnostic parameters have significant limitations and are not reliable for estimating body iron stores or predicting response to therapy 1
- Ferritin is an acute-phase reactant, making interpretation difficult in inflammatory conditions—ferritin levels up to 100 μg/L may still reflect iron deficiency in the presence of inflammation 6, 2
- Soluble transferrin receptor (sTfR) is more sensitive in inflammatory conditions where ferritin is unreliable, as it is elevated in ID but not affected by inflammation 3
Treatment Approaches
Absolute Iron Deficiency
- Oral iron monotherapy (100 mg elemental iron daily) is appropriate for patients without malabsorption or intolerance 6
- Intravenous iron is indicated for oral iron intolerance, malabsorption, or chronic inflammatory conditions 3, 2
- Hemoglobin should increase by 1-2 g/dL within 4-8 weeks of therapy 3
Functional Iron Deficiency
- Intravenous iron is strongly preferred over oral iron in most cases, especially in CKD patients on ESA therapy, as oral iron is poorly absorbed due to hepcidin-mediated blockade 2, 5
- Dosing strategy: Weekly IV iron (50-125 mg) for 8-10 doses until target hemoglobin is achieved or iron parameters normalize 2
- In chronic heart failure, IV iron has demonstrated prognostic benefit including reduced cardiovascular death, while oral iron has shown no benefit and should be avoided 6
- Maintenance therapy: Approximately 400-500 mg of supplemental iron every 3 months is needed to maintain adequate stores once target hemoglobin is reached 2
Distinguishing Functional Iron Deficiency from Inflammatory Block
- When uncertain, administer weekly IV iron (50-125 mg) for 8-10 doses as a therapeutic trial 2
- If no erythropoietic response occurs, inflammatory block is most likely, and IV iron should be discontinued until the inflammatory condition resolves 2
- This approach helps differentiate true functional iron deficiency (which responds to IV iron) from pure inflammatory anemia (which does not) 2
Monitoring and Safety
Laboratory Monitoring
- Assess hemoglobin, TSAT, and ferritin 4-8 weeks after the last infusion—do not evaluate iron parameters within 4 weeks of total dose infusion as circulating iron interferes with assays 3
- In hemodialysis patients, measure TSAT and ferritin at least every 3 months 7
- Target maintenance levels: TSAT ≥20% and ferritin ≥100 μg/L 7
Safety Thresholds
- Avoid chronically maintaining TSAT >50% or ferritin >800 μg/L in hemodialysis patients to prevent iron overload 7
- Iron overload can cause cirrhosis, diabetes, cardiomyopathy, and arthropathy 8
- Iron administration may increase infection risk, particularly with non-transferrin-bound iron promoting growth of siderophilic bacteria 7
Special Populations
Chronic Kidney Disease
- 15-72.8% of non-dialysis CKD patients have either ferritin <100 μg/L or TSAT <20% 1, 7
- Functional iron deficiency is particularly common in dialysis patients receiving ESA therapy 2, 4
Inflammatory Bowel Disease
- One-third of patients with active IBD have iron deficiency 6
- Ferritin levels up to 100 μg/L in the presence of inflammation may still reflect iron deficiency 6
- Oral iron should contain no more than 100 mg elemental iron daily; IV iron is indicated for intolerance or moderate-to-severe IDA (Hb <100 g/L) 6